Evgen Pharma plc
("Evgen Pharma" or the "Company")
SAS study clarification
Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, provides the following clarification:
Further to this morning's earlier announcement, the Company can confirm that it remains well funded to pursue commercial opportunities for SFX-01 in oncology and other disease areas. Evgen is unlikely to pursue the subarachnoid haemorrhage opportunity given the data announced earlier today. The reference to a strategic review relates to the significance of these data on related neurological indications.
Enquiries:
Evgen Pharma plc www.evgen.com |
via Walbrook |
Dr Stephen Franklin, CEO |
|
Richard Moulson, CFO |
|
|
|
finnCap www.finncap.com |
+44 (0) 20 7220 0500 |
Geoff Nash / Teddy Whiley (Corporate Finance) |
|
Alice Lane, Manasa Patil (ECM) |
|
|
|
WG Partners LLP |
+44 (0) 20 3705 9330 |
Nigel Barnes / Claes Spång |
|
|
|
Walbrook PR |
+44 (0)20 7933 87870 or [email protected] |
Paul McManus / Anna Dunphy |
+44 (0)7980 541 893 / +44 (0)7876 741 001 |
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
